Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28938326 | 1.00 | CD38 (0.67) | CD38 | |
| SCHEMBL23329118 | 0.84 | CD38 (0.67) | CD38 | |
| SCHEMBL30230488 | 0.84 | CD38 (0.67) | CD38 | |
| SCHEMBL28722484 | 0.83 | CD38 (0.61) | CD38 | |
| SCHEMBL28722482 | 0.83 | CD38 (0.61) | CD38 | |
| SCHEMBL22936261 | 0.81 | CD38 (0.69) | CD38 | |
| SCHEMBL28724588 | 0.81 | CD38 (0.67) | CD38 | |
| SCHEMBL22932663 | 0.81 | CD38 (0.67) | CD38 | |
| SCHEMBL28938319 | 0.81 | CD38 (0.69) | CD38 | |
| SCHEMBL22933148 | 0.81 | CD38 (0.51) | CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021021986-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | RIBON THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | CD38 1/4885 |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | CD38 1/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | CD38 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.